Pfizer COVID-19 vaccine safety data - Child participants COVID-19 vaccines Main navigation COVID-19 vaccines Moderna XBB.1.5 COVID-19 vaccine Pfizer XBB.1.5 COVID-19 vaccine Pfizer bivalent BA.4/5 COVID-19 vaccine Moderna bivalent COVID-19 vaccine Pfizer bivalent BA.1 COVID-19 vaccine Pfizer COVID-19 vaccine adult formulation Pfizer COVID-19 vaccine paediatric formulation (5–11 years) Moderna COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines National Immunisation Program schedule vaccines Mpox (monkeypox) vaccine Shingrix® Data on this page show the responses of individuals aged 5–11 years who received a paediatric 5–11 years formulation of the Pfizer COVID-19 vaccine (both monovalent original and XBB.1.5 variant) and whose parent or carer completed an AusVaxSafety survey on their behalf sent on day 3 after vaccination. These data provide a profile of what to expect in the days following a child’s Pfizer COVID-19 vaccination and can assist when planning for a child’s COVID-19 vaccination. Data on this page are updated monthly. AusVaxSafety’s active vaccine safety surveillance system complements the enhanced safety surveillance activities of the Therapeutic Goods Administration (TGA). Find out more about how the TGA monitors the safety of vaccines and how you can report side effects on the TGA website. News & events All news & events 28 March 2024 | News AusVaxSafety commences routine surveillance of 2024 seasonal influenza vaccines 08 March 2024 | News Vaccine safety in Australia AusVaxSafety summary report now available 20 February 2024 | News What to expect in the days after your XBB.1.5 COVID-19 vaccine 20 December 2023 | News Shingrix® vaccine safety data now available